Archive for the ‘the-field’ tag
ACT Announces that Additional Patient with Stargardt’s Disease Has Undergone Embryonic Stem Cell Transplantation at …
Advanced Cell Technology, Inc.
Read the original here:
ACT Announces that Additional Patient with Stargardt’s Disease Has Undergone Embryonic Stem Cell Transplantation at …
ACT Announces Europe’s First Human Embryonic Stem Cell Transplant in Patient with Stargardt’s Disease
Advanced Cell Technology, Inc. , a leader in the field of regenerative medicine, today announced treatment of the first patient in its Phase 1/2 clinical trial for Stargardt’s macular dystrophy using retinal pigment epithelial cells derived from human embryonic stem cells .
Follow this link:
ACT Announces Europe’s First Human Embryonic Stem Cell Transplant in Patient with Stargardt’s Disease
Leading Eye Institute to Participate in ACT’s Embryonic Stem Cell Clinical Trial for Macular Degeneration
Advanced Cell Technology, Inc. , a leader in the field of regenerative medicine, today announced that the Wills Eye Institute in Philadelphia has received insti
Follow this link:
Leading Eye Institute to Participate in ACT’s Embryonic Stem Cell Clinical Trial for Macular Degeneration
Advanced Cell Technology to Present at 2011 Stem Cell Meeting on the Mesa’s Investor and Partnering Forum
MARLBOROUGH, Mass.–(BUSINESS WIRE)–Advanced Cell Technology, Inc.
See the original post:
Advanced Cell Technology to Present at 2011 Stem Cell Meeting on the Mesa’s Investor and Partnering Forum
Advanced Cell Technology to Present at 2011 Stem Cell Meeting on the Mesas Investor and Partnering Forum
Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that the company’s director of business development, Matthew Vincent, Ph.D., will be presenting at the 2011 Stem Cell Meeting on the Mesa’s Investor and Partnering Forum, Nov. 30 to Dec
European Ruling May Not Impact Stem Cell Lines Derived Using Advanced Cell Technology’s Single-Blastomere Method
Advanced Cell Technology, Inc.
The rest is here:
European Ruling May Not Impact Stem Cell Lines Derived Using Advanced Cell Technology’s Single-Blastomere Method
BioTime CEO Michael D. West to Present at GTC 2011 5th Advances in Stem Cell Discovery & Development Conference
BioTime, Inc. (NYSE Amex:BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that …
Go here to see the original:
BioTime CEO Michael D. West to Present at GTC 2011 5th Advances in Stem Cell Discovery & Development Conference
Press Release
BioTime Inc. Posted on:29 Sep 11 BioTime, Inc
Read this article:
Press Release
BioTime CEO Dr. Michael West to Present at 2011 World Stem Cell Summit
BioTime, Inc. (NYSE Amex: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that …
More:
BioTime CEO Dr. Michael West to Present at 2011 World Stem Cell Summit
ACT Receives Approval for First Human Embryonic Stem Cell Trial in Europe
Advanced Cell Technology, Inc. ;, a leader in the field of regenerative medicine, announced today that it has received clearance from the U.K. Medicines and Healthcare products Regulatory Agency to begin treating patients as part of a Phase 1/2 clinical trial for Stargardt’s Macular Dystrophy using retinal pigment epithelium derived from human embryonic stem cells .
Read the rest here:
ACT Receives Approval for First Human Embryonic Stem Cell Trial in Europe